Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
The FDA approves Effient, Lilly's blood thinner, reports CNBC's Mike Huckman.
The hour's top business headlines, with CNBC's Mike Huckman.
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

PHARMA'S MARKET VIDEO

» More

Current DateTime: 08:46:43 11 Jul 2009
LinksList Documentid: 31171988
Expiration DateTime: 7/11/2009 8:48:08 PM

RSS FEED

» Help

Current DateTime: 08:46:44 11 Jul 2009
LinksList Documentid: 31171995
Pharma's Market Blog
Text Size
Mar.05
8:15 AM ET
Wednesday, 5 Mar 2008
Baxter, Biogen Idec & Elan Subjects of Broken Embargoes

I've blogged many times about the embargoes imposed by scientific groups and medical journals. If a media outlet breaks one -- something I have not done -- they risk losing the "privilege" of receiving the info ahead of time. And there's been a recent example of a prominent doctor who spoke too soon and has been barred for a while from publishing and reviewing studies in a peer-reviewed journal. Well, now at least one organization may take the enforcement a step further.

Reuters broke the story that three research analysts -- one at Merrill Lynch, another at Natexis Bleichroeder and the third at JPMorgan -- issued reports earlier this week with embargoed data from the upcoming American Academy of Neurology conference.

Two of the research notes to clients were about an experimental Alzheimer's drug from Baxter [BAX  Loading...      ()   ]. And the other note focused on the MS drug Tysabri from BIIB [BIIB  Loading...      ()   ] and ELN [ELN  Loading...      ()   ].

Reuters says the JPM and Natexis reports were retracted or recalled and that Merrill declined to comment.

But a spokesperson for the AAN says the recall or retraction may not be sufficient and that the organization could possibly try to take some kind of legal action. Here's their statement:

“The American Academy of Neurology is disappointed that representatives of financial organizations have deliberately violated the Academy’s embargo policy. The violation has been referred to the Academy’s General Counsel who is currently exploring all options available to the Academy.”

The embargo issue keeps cropping up for the organizations and journals that are trying to protect their "scientific integrity" and potentially headline-making content while servicing the companies that often sponsor the research (and the conferences) and in which Wall Street has a vested interest.

It will once again be put to the test over the next couple of months when the most widely-followed conference by doctors, scientists, investors, reporters and analysts--the American Society of Clinical Oncology annual meeting--employs a new policy this year with some of its data to try to satisfy everyone.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post


Current DateTime: 01:07:47 11 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 01:07:47 11 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 07:18:53 11 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:06:09 11 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters